Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Anal Canal Carcinoma, Anus Neoplasms

Carcinoma, Renal Cell, Lymphatic Metastasis

Oropharyngeal Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Renal Cell

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Kidney Neoplasms

Urothelial Cancer

Adenocarcinoma Of Esophagus, Stomach Neoplasms

Adenocarcinoma Of Esophagus

Mesothelioma, Malignant, Mesothelioma

Lung Neoplasms

Neoplasm Metastasis, Stomach Neoplasms

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

Carcinoma, Hepatocellular

Various Advanced Cancer

Carcinoma, Renal Cell, von Hippel-Lindau Disease

Urinary Bladder Neoplasms

Mesothelioma, Malignant, Mesothelioma

Advanced Kidney Cancer

Carcinoma, Non-Small-Cell Lung

Colonic Neoplasms

Clinical Trials

ANVIL

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

eVOLVE-RCC02

CheckMate901

STAR-221

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

eVOLVE-Meso

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

CIME

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

CheckMate 9DW

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

CheckMate 648

MK-6482-043

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

DREAM3R

The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.

A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

RELATIVITY-098

CheckMate 816

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer